Xin Meiying, Hao Yulei, Huang Ge, Wang Xu, Liang Zhen, Miao Jing, Ma Di, Feng Jiachun
Department of Neurology, The First Hospital of Jilin University.
Department of Radiology, the Second Bethune Hospital of Jilin University, Changchun, Jilin, China.
Medicine (Baltimore). 2020 Jun 5;99(23):e20059. doi: 10.1097/MD.0000000000020059.
Salvianolic acids (SA) has been widely used for the treatment of acute cerebral infarction (ACI) combined with basic western medicine therapy in China. This study was aimed to evaluate the efficacy and safety of SA on ACI treatment and its influence on neurological functions, activity of daily living, and cognitive functions.
We retrieved related articles from PubMed, the Cochrane Center Controlled Trials Register, EMBASE, Medline, Ovid, Chinese National Knowledge Infrastructure, Chinese Biomedical Literature Database, and Wanfang Database without date and language restrictions. Finally, 58 randomized controlled trials were included from 239 retrieved records. Two researchers extracted the basic information and data from included articles and assessed the quality and analysis of data by using Review Manager 5.3.
The administration of SA significantly increased the total clinical effective rate of ACI treatment (P < .001) and improved the National Institute of Health Stroke Scale scores, modified Rankin Scale scores, and Barthel Index scores after treatment and 3 months after ACI (P < .05). The activities of daily living scores in the SA group were significantly increased after treatment (P < .001), whereas they were remarkably decreased 3 months after ACI (P < .001) compared with that in the control group. Besides, SA profoundly promoted the recovery of Montreal Cognitive Assessment scores (P < .001). However, the use of SA increased the risk of adverse events occurrence (P = .007).
SA combined with basic western medicine treatment could promote neurological functions, daily living activities, and cognitive functions recovery of ACI patients. Although SA increased the risk of adverse events occurrence, these adverse events were easily controlled or disappeared spontaneously.
在中国，丹参酸已广泛用于联合基础西医治疗急性脑梗死（ACI）。本研究旨在评估丹参酸治疗ACI的疗效和安全性及其对神经功能、日常生活活动能力和认知功能的影响。
我们从PubMed、Cochrane中心对照试验注册库、EMBASE、Medline、Ovid、中国知网、中国生物医学文献数据库和万方数据库中检索相关文章，无日期和语言限制。最终，从检索到的239条记录中纳入了58项随机对照试验。两名研究人员从纳入的文章中提取基本信息和数据，并使用Review Manager 5.3评估数据质量和进行分析。
丹参酸的使用显著提高了ACI治疗的总临床有效率（P<0.001），并改善了治疗后及ACI发生后3个月的美国国立卫生研究院卒中量表评分、改良Rankin量表评分和Barthel指数评分（P<0.05）。丹参酸组治疗后的日常生活活动能力评分显著提高（P<0.001），而与对照组相比，ACI发生后3个月显著降低（P<0.001）。此外，丹参酸显著促进了蒙特利尔认知评估评分的恢复（P<0.001）。然而，丹参酸的使用增加了不良事件发生的风险（P=0.007）。
丹参酸联合基础西医治疗可促进ACI患者神经功能、日常生活活动能力和认知功能的恢复。虽然丹参酸增加了不良事件发生的风险，但这些不良事件易于控制或自行消失。
